Overview

Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

Status:
COMPLETED
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the potential therapeutic effects of the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatment for rheumatoid arthritis patients with variant disease activity.
Phase:
PHASE2
Details
Lead Sponsor:
Tanta University
Treatments:
Ursodeoxycholic Acid